Immunological and histopathological tumor responses to a novel neoadjuvant peptide vaccine (CYT001) targeting HSP70 and GPC3 antigens in patients with resectable HCCMasao Nakajima1, Shoichi Hazama1, Koji Tamada1, Keiko Udaka2, Shun Doi3, Michiie Sakamoto4, Akira Saito5, Shiro Akinaga6, Hiroto Matsui1, Yoshitaro Shindo1, Satoshi Matsukuma1, Yukio Tokumitsu1, Shinobu Tomochika1, Michihisa Iida1, Shin Yoshida1, Ryouichi Tsunedomi1, Yuki Nakagami1, Nobuaki Suzuki1, Shigeru Takeda1, Naoya Kato7, Hiroaki Nagano1

1 Yamaguchi University, Ube, Yamaguchi, Japan; 2 Kochi University, Nangoku, Kochi, Japan; 3 CYTLIMIC Inc., Shinagawa, Tokyo, Japan; 4 Keio University, Shinjukuku, Tokyo, Japan; 5 Tokyo Medical University, Shinjukuku, Tokyo, Japan; 6 AccuRna Incorporation, Bunkyoku, Tokyo, Japan; 7 Chiba Yuniversity, Chuoku, Chiba, Japan

Poster number: CT251